- PDX models of tumors offer better in vivo insights for cancer research and drug development
- Highly characterized models, originally exclusively licensed from The Wistar Insitute
Cambridge, UK, 26 May 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announced it has added four BRAF-resistant melanoma PDX (patient derived xenograft) models to its range of commercially available in vivo models to support drug efficacy studies.
PDX models are created by implanting cancerous tissue from a human primary tumor directly into immunodeficient mouse or rat models, enabling acceleration of oncology research or drug discovery and development programs. PDX models may be used to support studies including preclinical drug screening, preclinical combination therapeutics screening, or identification and analysis of biomarkers. The BRAF-resistant melanoma models available from Horizon have been highly characterized, including comprehensive patient histories, sequencing analysis data, and protein expression data.
Dr. Chris Eden, Product Manager, Horizon Discovery, commented: “It is becoming increasingly apparent that individual genetics can have a powerful impact on the efficacy and toxicology of therapeutics. By understanding which genes and genotypes can impact a drug, not only can the right drug be directed to the right patient at the right dose, but more efficient clinical trials can be designed, offering the promise of less costly, faster, and lower risk trials for pharmaceutical partners.”
Horizon’s has partnered with The Wistar Institute of Anatomy and Biology in Philadelphia, Pennsylvania to make available their large collection of highly characterized Melanoma PDX models to the research community. These melanoma models are representative of all previously well-described melanoma subtypes identified by the Cancer Genome Atlas (TCGA).
More information on Horizon Discovery’s range of PDX models can be found here: https://www.horizondiscovery.com/patient-derived-xenograft